Abstract: TH-PO834
Curcumin: A Nutritional Strategy to Control Oxidative Stress in Patients Undergoing Peritoneal Dialysis
Session Information
- Health Maintenance, Nutrition, Metabolism
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Health Maintenance‚ Nutrition‚ and Metabolism
- 1400 Health Maintenance‚ Nutrition‚ and Metabolism
Authors
- Mafra, Denise, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Reis, Drielly Cristhiny Mendes de Vargas, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Baptista, Beatriz Germer, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Cardozo, Ludmila Fmf, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Ribeiro-Alves, Marcelo, Fundacao Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
- de Paiva, Bruna Regis, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Alvarenga, Livia De almeida, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Fouque, Denis, Universite Claude Bernard Lyon 1, Villeurbanne, Auvergne-Rhône-Alpes , France
- Leite, Maurilo, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
Background
Patients with chronic kidney disease (CKD) on peritoneal dialysis (PD) present a high production of reactive oxygen species (ROS) that lead to oxidative stress and inflammation. Bioactive compounds such as curcumin (from turmeric) have been tested as nutritional strategies to mitigate both complications. The aim of this study was to evaluate the effect of curcumin supplementation on lipid peroxidation and inflammatory markers in patients with CKD on PD.
Methods
In this longitudinal, randomized, single-blind, placebo-controlled trial, 42 patients were randomized into two groups: curcumin (1.5g/d with 98.42% of curcuminoids) or placebo for 3 months. The malondialdehyde (MDA) plasma levels (lipid peroxidation marker) and TNF-α and IL-6 were measured before and after the intervention.
Results
Twenty-four patients completed the study, 10 in the curcumin group (54 yr, 3 men) and 14 in the placebo group (52 yr, 5 men). MDA plasma levels were significantly reduced after three months of curcumin supplementation (Figure 1), whereas remained unchanged in the placebo group. The inflammation markers did not change after intervention in both groups.
Conclusion
Curcumin supplementation may be a good strategy to reduce oxidative stress in patients undergoing PD.
Funding
- Government Support – Non-U.S.